Please login to the form below

Not currently logged in
Email:
Password:

kidney cancer

This page shows the latest kidney cancer news and features for those working in and with pharma, biotech and healthcare.

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

little longer before it can bring it forward for RCC, the most common form of kidney cancer. ... line use of the pair in non-small cell lung cancer (NSCLC) based on the IMpower150 study, delaying its verdict by three months.

Latest news

More from news
Approximately 22 fully matching, plus 115 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo ... up innate immune responses, and

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... Additional revenues for

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... This protracted process is indicative of the now

  • Pharma investment in Indonesia Pharma investment in Indonesia

    Under this universal scheme, all healthcare services and drugs for major diseases, such as cancer, chronic kidney disease etc.

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    NHS Diabetes and Kidney Care and the National Cancer Action Team, have been amalgamated into more wide-reaching bodies that are aiming to reshape the healthcare environment in England. ... UK. Referencing the industry's work in HIV and cancer, Prof

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time ... This background will benefit Mirna, which has just

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

  • A stumble, but not a fall – what’s next for Opdivo?

    and renal cell carcinoma (kidney cancer). ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics